In summary, our systems biology approach that integrates multimodal omics and phenotype data across species with experimental validations discovered DDR2, STOM and KANK2 as potential therapeutic targets in PSP. The gene discussed is DDR2; the disease is supranuclear palsy, progressive, 1.